NanoViricides' NV-387 Shows No Adverse Effects in Juvenile Mouse Study

By Public Technologies
  • NanoViricides reported Oct. 20, 2026, that its antiviral candidate NV-387 showed no treatment-related adverse effects in a juvenile mouse study.
  • The highest tested dose was 1,230 mg/kg three times daily, totaling 3,690 mg/kg/day over 12 days.
  • No mortality or systemic toxicity occurred; a maximum tolerated dose could not be determined because the highest dose was well tolerated.
  • The study included a 14-day recovery period to assess persistent, reversible or delayed treatment effects.
  • NV-387 oral gummies are currently in separate Phase II trials for Ebola and Mpox in the Democratic Republic of Congo.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610200845ACCESSWRNAPR_____1238833) on October 20, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk